Sanofi SA
SNY
View Detailed Chart
47.830USD
+0.340+0.72%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
115.64BMarket Cap
13.25P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.72%
5 Days
+1.68%
1 Month
-0.71%
6 Months
+3.57%
Year to Date
-1.30%
1 Year
-9.53%
View Detailed Chart
TradingKey Stock Score of Sanofi SA
Currency: USD Updated: 2026-02-06Key Insights
Sanofi SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 42 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 59.77.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Sanofi SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Sanofi SA Highlights
StrengthsRisks
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 17.07% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 52.67B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 171.67%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 171.67%.
Undervalued
The company’s latest PE is 13.25, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 242.12M shares, decreasing 8.93% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 34.20K shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
59.768
Target Price
+25.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Sanofi SA News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Sanofi SA Info
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Ticker SymbolSNY
CompanySanofi SA
CEOHudson (Paul)
Websitehttps://www.sanofi.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69181.990
-788.140 (-1.13%)
282.580
+22.390 (+8.61%)
2043.900
-7.830 (-0.38%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
